Fin­land's Faron ham­mered by sur­pris­ing piv­otal tri­al flop; CFO Si­mon Dinge­mans ex­its GSK in lead­er­ship makeover

→ A piv­otal tri­al dis­as­ter has caught Faron Phar­ma­ceu­ti­cals’ ex­ecs by sur­prise and crushed its stock. The Finnish biotech re­port­ed Tues­day that its lead drug …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER